Our BSP analysis demonstrated that the methylation levels of CDKN1C promoter are significantly higher in AML patients than that of the healthy controls, and MBD2 deficiency did not affect the methylation status of CDKN1C promoter regions in leukemia cells. Here, MBD2 is linked to acute myeloid leukemia.